PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Advocate-BREAST80+: A Comprehensive Patient and Advocate-Led Study to Enhance Breast Cancer Care Delivery and Patient-Centered Research in Women aged ≥ 80 years
O’Sullivan, C.C.; Vierkant, R.A.; Larson, N.L.; Smith, M.L.; Chauhan, C.; Couch, F.J.; Olson, J.E.; D’Andre, S.; Jatoi, A.; Ruddy, K.J. Advocate-BREAST80+: A Comprehensive Patient and Advocate-Led Study to Enhance Breast Cancer Care Delivery and Patient-Centered Research in Women Aged ≥80 Years. Cancers2024, 16, 2494.
O’Sullivan, C.C.; Vierkant, R.A.; Larson, N.L.; Smith, M.L.; Chauhan, C.; Couch, F.J.; Olson, J.E.; D’Andre, S.; Jatoi, A.; Ruddy, K.J. Advocate-BREAST80+: A Comprehensive Patient and Advocate-Led Study to Enhance Breast Cancer Care Delivery and Patient-Centered Research in Women Aged ≥80 Years. Cancers 2024, 16, 2494.
O’Sullivan, C.C.; Vierkant, R.A.; Larson, N.L.; Smith, M.L.; Chauhan, C.; Couch, F.J.; Olson, J.E.; D’Andre, S.; Jatoi, A.; Ruddy, K.J. Advocate-BREAST80+: A Comprehensive Patient and Advocate-Led Study to Enhance Breast Cancer Care Delivery and Patient-Centered Research in Women Aged ≥80 Years. Cancers2024, 16, 2494.
O’Sullivan, C.C.; Vierkant, R.A.; Larson, N.L.; Smith, M.L.; Chauhan, C.; Couch, F.J.; Olson, J.E.; D’Andre, S.; Jatoi, A.; Ruddy, K.J. Advocate-BREAST80+: A Comprehensive Patient and Advocate-Led Study to Enhance Breast Cancer Care Delivery and Patient-Centered Research in Women Aged ≥80 Years. Cancers 2024, 16, 2494.
Abstract
Background: There are limited evidence-based data to guide treatment recommendations for breast cancer (BC) patients ≥ 80 years (P80+). Identifying and addressing unmet needs are critical.
Aims: Advocate-BREAST80+ compared the needs of P80+ vs. patients < 80 years (P80-).
Methods: In 12/2021, a REDCap survey was circulated electronically to 6,918 persons enrolled in the Mayo Clinic Breast Disease Registry. The survey asked about concerns and satisfaction with multiple aspects of BC care.
Results: 2,437 participants responded (35 % response rate); 202 (8.3%) were P80+. P80+ were less likely to undergo local regional and systemic therapies vs. P80- (p
Public Health and Healthcare, Public Health and Health Services
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.